AKLI vs. FEMY, RVP, ICU, NMTC, MDAI, IINN, LNSR, MODD, LYRA, and CODX
Should you be buying Akili stock or one of its competitors? The main competitors of Akili include Femasys (FEMY), Retractable Technologies (RVP), SeaStar Medical (ICU), NeuroOne Medical Technologies (NMTC), Spectral AI (MDAI), Inspira Technologies Oxy B.H.N. (IINN), LENSAR (LNSR), Modular Medical (MODD), Lyra Therapeutics (LYRA), and Co-Diagnostics (CODX). These companies are all part of the "surgical & medical instruments" industry.
Femasys (NASDAQ:FEMY) and Akili (NASDAQ:AKLI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking.
Femasys has a net margin of -1,420.59% compared to Femasys' net margin of -3,545.47%. Femasys' return on equity of -76.34% beat Akili's return on equity.
In the previous week, Femasys had 3 more articles in the media than Akili. MarketBeat recorded 8 mentions for Femasys and 5 mentions for Akili. Femasys' average media sentiment score of 0.75 beat Akili's score of 0.46 indicating that Akili is being referred to more favorably in the news media.
Femasys currently has a consensus target price of $11.67, suggesting a potential upside of 803.62%. Akili has a consensus target price of $4.00, suggesting a potential upside of 806.41%. Given Femasys' higher probable upside, analysts clearly believe Akili is more favorable than Femasys.
Femasys has a beta of -2.76, suggesting that its stock price is 376% less volatile than the S&P 500. Comparatively, Akili has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.
Femasys received 16 more outperform votes than Akili when rated by MarketBeat users. However, 66.67% of users gave Akili an outperform vote while only 64.71% of users gave Femasys an outperform vote.
Femasys has higher earnings, but lower revenue than Akili. Femasys is trading at a lower price-to-earnings ratio than Akili, indicating that it is currently the more affordable of the two stocks.
65.3% of Femasys shares are owned by institutional investors. Comparatively, 53.1% of Akili shares are owned by institutional investors. 16.4% of Femasys shares are owned by company insiders. Comparatively, 10.1% of Akili shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Akili beats Femasys on 9 of the 17 factors compared between the two stocks.
Get Akili News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
